COVID-19 Funding Snapshot for Pharma Developers/Manufacturers Views as of August 7, 2020 Presentations August 21, 2020 Lain Anderson Cassie Guo Adam Nover
Contributing authors: Tony Stripling, Associate Consultant Sean Saunders, Life Sciences Speciaist Jennifer Henry, Associate Consultant Patrick Marquet, Associate Related Practice Life Sciences & Pharma The COVID-19 pharmaceutical funding landscape is evolving at a rapid pace, yet several initial insights have emerged 01262022160100
Video / Webinar Healthcare Services AI in Healthcare: Passive, Reactive, or Proactive? August 2, 2024
Podcast Life Sciences & Pharma A New Generation of Drug Therapies Requires New Business Strategies July 10, 2024
Executive Insights Mental and Behavioral Health Psychedelics and Psychotherapy: A Treatment Paradigm for the Future? March 27, 2024
Executive Insights Business Services Benefits of the 4-Day Week: The Jury Is Still Out October 31, 2023